Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05574504 |
| Title | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | AdventHealth |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| AdventHealth Cancer Institute | Orlando | Florida | 32804 | United States | Details |